{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:19:03Z","timestamp":1775819943598,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.semnephrol.2004.06.006","type":"journal-article","created":{"date-parts":[[2008,9,21]],"date-time":"2008-09-21T13:22:07Z","timestamp":1222003327000},"page":"460-463","source":"Crossref","is-referenced-by-count":16,"title":["Calcimimetic agents for the treatment of secondary hyperparathyroidism"],"prefix":"10.1016","volume":"24","author":[{"given":"William G.","family":"Goodman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2004.06.006_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1523-1755.1998.00735.x","article-title":"A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication","volume":"53","author":"Antonsen","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0022-3565(24)34924-9","article-title":"NPS R-568","volume":"290","author":"Fox","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1385\/ENDO:10:2:97","article-title":"The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism","volume":"10","author":"Fox","year":"1999","journal-title":"Endocrine"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib5","doi-asserted-by":"crossref","first-page":"C382","DOI":"10.1152\/ajpcell.2001.280.2.C382","article-title":"Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line","volume":"280","author":"Yamaguchi","year":"2001","journal-title":"Am J Physiol"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1006\/bbrc.1998.8178","article-title":"Expression of extracellular calcium (Ca2+o)-sensing receptor in the clonal osteoblast-like cell lines, UMR-106 and SAOS-2","volume":"243","author":"Yamaguchi","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium \u00d7 phosphorus product levels in hemodialysis patients with secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib10","first-page":"764","article-title":"Short-term treatment of secondary hyperparathyroidism with the calcimimetic agent AMG 073","volume":"12","author":"Dr\u00fceke","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2004.06.006_bib11","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929504000890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929504000890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T01:14:51Z","timestamp":1738372491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929504000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0270929504000890"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2004.06.006","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}